Sold as Lumoxiti. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Moxetumomab Pasudotox-Tdfk (sold as Lumoxiti), first approved Sep 13, 2018, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell LeukemiaHairy Cell Leukemia · National Cancer Institute (NCI) | Phase 1 | Active, not recruiting | Jan 16, 2019 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Sep 13, 2018 | LumoxitiBLA 761104 · New molecular entity | Innate Pharma | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA